StockNews.AI
TVTX
StockNews.AI
187 days

Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

1. Travere will release Q4 and full-year 2024 results on February 20. 2. A conference call will follow to discuss financial results and updates. 3. The webcast will be archived for 30 days post-event for investor access.

Earnings
-3.41%Current Return
VS
0%S&P 500
$23.7202/13 04:34 PM EDTEvent Start
$22.9102/14 10:49 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Neutral?

Upcoming financial results do not guarantee significant movement without surprises, similar to past reports.

How important is it?

Earnings reports can influence investor sentiment, but results must meet expectations for impact.

Why Short Term?

Immediate market response expected post-results announcement; longer-term effect depends on actual performance.

Related Companies

TVTX
SAN DIEGO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2024 financial results on Thursday, February 20, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere’s website at ir.travere.com/events-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company’s website. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com. Contact Info

Related News